FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safety

Regulatory Toxicology and Pharmacology 2026

View at publisher
Authors: Mineo Matsumoto, J.Ryan Polli, Suresh Kumar Swaminathan, Kaushik Datta, Cris Kamperschroer, Marie C. Fortin, Smita Salian‐Mehta, Rutwij Dave, Zheng Yang, Payal Arora, Masanori Hiura, Mizuho Suzuki
+3 more Christine Crute, Frank R. Brennan, Jean G. Sathish
DOI: 10.1016/j.yrtph.2026.106038
Cited by: 0
References: 17

Fields of Study & Subjects

Statistical Methods in Clinical Trials Pharmaceutical studies and practices Immunotoxicology and immune responses

Publication details

Journal / source
Regulatory Toxicology and Pharmacology
Volume
168
Pages
106038–106038
Publication date
30 January 2026
Language
EN